Get the Stockscreener App
40.23
0.56%
0.2454
Roivant Sciences Ltd stock is traded at $40.23, with a volume of 5.49M.
It is up +0.56% in the last 24 hours and up +7.59% over the past month.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
See More
Previous Close:
$39.98
Open:
$40.11
24h Volume:
5.49M
Relative Volume:
0.83
Market Cap:
$29.05B
Revenue:
$8.26M
Net Income/Loss:
$-397.91M
P/E Ratio:
-79.88
EPS:
-0.5036
Net Cash Flow:
$-758.56M
1W Performance:
-1.51%
1M Performance:
+7.59%
6M Performance:
+44.62%
1Y Performance:
+166.43%
1-Day Range:
$39.73
$40.71
1-Week Range:
$39.16
$41.60
52-Week Range:
$14.50
$42.50
Roivant Sciences Ltd Stock (ROIV) Company Profile
Name
Roivant Sciences Ltd
Sector
Industry
Phone
441-295-5950
Address
7TH FLOOR, 50 BROADWAY, LONDON
Compare ROIV vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
40.22 | 29.49B | 8.26M | -397.91M | -758.56M | -0.5036 |
VRTX
Vertex Pharmaceuticals Inc
|
509.02 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
787.26 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.48 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
154.80 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
189.91 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-20-26 | Initiated | Bernstein | Outperform |
| Sep-02-25 | Initiated | Citigroup | Buy |
| Jul-10-25 | Resumed | Goldman | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Jan-05-24 | Initiated | Piper Sandler | Overweight |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-17-23 | Initiated | Guggenheim | Buy |
| Jun-08-23 | Initiated | BofA Securities | Neutral |
| Oct-27-22 | Initiated | JP Morgan | Overweight |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-29-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-15-21 | Initiated | Goldman | Buy |
| Nov-08-21 | Initiated | H.C. Wainwright | Buy |
| Oct-28-21 | Initiated | Citigroup | Buy |
| Oct-26-21 | Initiated | Cowen | Outperform |
| Oct-26-21 | Initiated | Jefferies | Buy |
| Oct-26-21 | Initiated | Truist | Buy |
View All
Roivant Sciences Ltd Stock (ROIV) Latest News
ROIV gains commercial footing with LISRAYA appr... - Pluang
Roivant Sciences: Diverse Exposure To Biotech Niches Through Vants (NASDAQ:ROIV) - Seeking Alpha
Roivant Sciences Ltd. (ROIV)’s Pulmonary Hypertension Breakthrough Could Transform Its Growth Story - Yahoo Finance
(ROIV) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Roivant Sciences (ROIV) Could Be 308% Overvalued Following Phase 2 Mosliciguat Data - simplywall.st
ROIV Stock Nears Record High –Retail Traders See Breakout After Surprise Earnings Beat - Stocktwits
Roivant Sciences (ROIV) director sells stock under preset plan - Stock Titan
Roivant Sciences Ltd. (ROIV) Discusses Top Line Results from PHocus Study of Mosliciguat in PH-ILDSlideshow - Seeking Alpha
ROIV: FDA approval, best-in-class PH-ILD data, and robust pipeline drive strong outlook - TradingView
Did Phase 2 Trial Win Just Shift Roivant Sciences (ROIV) Investment Narrative? - simplywall.st
ROIV: Robust pipeline advances and strong financials set the stage for multiple upcoming launches - TradingView
Roivant at Citi summit: cash-rich biotech leans on three pillars - Investing.com India
Why Did Roivant (NASDAQ:ROIV) Shares Surge on Study Results? - Kalkine Media
Roivant Sciences Company Profile & Introduction - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
A Quick Look at Today's Ratings for Roivant Sciences(ROIV.US), With a Forecast Between $46 to $55 - Moomoo
ROIV Maintains Buy Rating -- Price Target Raised to $55 - GuruFocus
Roivant Reports 56.3% Placebo-Adjusted PVR Reduction In Phase 2 Mosliciguat PH-ILD Study, Starts Phase 3 PHrontier Trial - Pulse 2.0
Guggenheim raises Roivant Sciences stock price target on trial data By Investing.com - Investing.com Australia
TD Cowen raises Roivant Sciences stock price target on trial data - Investing.com Australia
H.C. Wainwright raises Roivant Sciences price target on trial data - investing.com
Guggenheim raises Roivant Sciences stock price target on trial data - Investing.com
Roivant Sciences Stock Rallies 20% On Positive Phase 2 Trial Results For Pulmovant Drug - TIKR.com
Roivant Sciences stock surges on positive PH-ILD trial data By Investing.com - Investing.com Australia
Why Did DELL, ROIV, SHEL Stocks Surge To 52-Week Highs Today? - finance.yahoo.com
Roivant (ROIV) Soars to All-Time High; Q2 Hedge Fund Holdings Surge 41% - Yahoo Finance
TD Cowen Maintains Roivant Sciences(ROIV.US) With Buy Rating, Raises Target Price to $55 - Moomoo
Why is Roivant Sciences stock surging today? By Investing.com - Investing.com Australia
Biotech Trial Wins Sent Roivant And Pharvaris Higher - Finimize
Roivant Sciences Ltd. (ROIV) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
ROIV Looks 472.1% Overvalued on GF Value™ Amid Clinical Trial Su - GuruFocus
Roivant Sciences soars 19% on positive mosliciguat trial results (ROIV:NASDAQ) - Seeking Alpha
Roivant Sciences (NASDAQ: ROIV) director moves to sell shares after option exercise - Stock Titan
Roivant Sciences Surges 17.7% Amid Sector-Wide Rally - AlphaStreet
ROIV Maintained by HC Wainwright & Co. -- Price Target Raised to $47 - GuruFocus
Roivant's experimental lung disease drug meets goals in mid-stage study - Reuters
These 2 Biotech Stocks Hit Record Highs Today – What’s Driving The Rallies? - Yahoo Finance
Roivant shares jump 17% as lung disease drug meets trial goals - Investing.com Canada
Jefferies raises Roivant Sciences stock price target on trial data By Investing.com - Investing.com South Africa
Roivant Sciences price target jumps 24.7% after strong Phase 2 trial for lung disease drug - Pluang
Roivant Sciences Stock Soars as Experimental Inhaled Drug Hits Mid-Stage Trial Goals - barrons.com
ROIV Stock Jumps As FDA Clears LISRAYA And Analysts Hike Targets - StocksToTrade
ROIV Stock Jumps As LISRAYA FDA Approval Ignites Momentum - timothysykes.com
Roivant at Wells Fargo conference: pipeline momentum lifts outlook By Investing.com - Investing.com Canada
Transcript : Roivant Sciences Ltd. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-08-2026 10:15 AM - marketscreener.com
Crude Oil Gains 1.5%; ABM Posts Upbeat Q3 Earnings - Benzinga
Jefferies Maintains Roivant Sciences(ROIV.US) With Buy Rating, Raises Target Price to $52 - Moomoo
Roivant Shares Surge as Mosliciguat Hits Primary Endpoint in Phase 2 PH-ILD Study - Minichart
Roivant Sciences Rallies as Mosliciguat Phase 2 Data Beat Key Endpoints - quiverquant.com
Roivant surges on ‘exceptional’ results; Bristol Myers touts first-of-its-kind CAR-T therapy - Yahoo Finance
Roivant’s pulmonary hypertension drug shines with ‘blowout’ Phase 2 data - BioSpace
Roivant Sciences Ltd Stock (ROIV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Roivant Sciences Ltd Stock (ROIV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Fitzgerald Meghan | Director |
Sep 15 '26 |
Sale |
39.74 |
5,112 |
203,152 |
36,108 |
2.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):